In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forest gets exclusive US rights to Nycomed's Daxas

Executive Summary

Forest Laboratories has licensed exclusive US marketing rights to fellow specialty drug company Nycomed's Daxas (roflumilast). Nycomed, which is developing the selective once-daily PDE4 enzyme inhibitor for symptomatic COPD, filed an NDA last month after completing four Phase III trials.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies